{"name":"AvenCell Therapeutics, Inc.","slug":"avencell-therapeutics-inc","ticker":"","exchange":"","domain":"avencell.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Allo-QuadCAR01-T","genericName":"Allo-QuadCAR01-T","slug":"allo-quadcar01-t","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"Allo-QuadCAR01-T","genericName":"Allo-QuadCAR01-T","slug":"allo-quadcar01-t","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"trial","source":"PR Newswire","summary":"AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Ref","headline":"AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZklZNXBBSi1YalNSSHVTTU9UaEFqZmtjUS1ybUliaG1RUXp0bEQtX1ZuVEN3c0RMY0ZIUlJGR0lzMldWZWZlUGhQTlVRcEgzTGFaQWw5cTFQTmVEQzF2bFVBY3luMU5fa0FuQjNyR2V0WXFZNjFpQ21DTmh5YmxKZ0RKMW1mNHlJcjdoZXBNUWpDcll1T2d0elpoY2NQZDNkeUVJQVY3cjluYnhHN3MyUkM0REJxUkZlQ2hr?oc=5","date":"2026-02-11","type":"trial","source":"Fierce Biotech","summary":"'The only thing that saves us is data': Allogeneic CAR-T biotechs fight for relevance as industry moves on - Fierce Biotech","headline":"'The only thing that saves us is data': Allogeneic CAR-T biotechs fight for relevance as industry moves on","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-04","type":"regulatory","source":"PR Newswire","summary":"AvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Study, a Phase I/II trial evaluating AVC-203, a Novel Allogeneic CD19/CD20 CAR-T In","headline":"AvenCell Therapeutics Announces IND Clearance and EMA Approval of Clinical Trial Application (CTA) for the QUADvance Stu","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxPUDhrSnpfenYwNi1mbk93dm1vX2xRaUlHSnNUb0J6N1JPWEpJYmpmMjh5ZTRkRnI0c2UxbEtzS3FnRGZZZG5qeUc4a29lMHZjTzU2WGNGeXNfaWdUQS1aMEhvOUJsLXBzb3VreXZtOUlnVW1MTzF2eEwtSXdDVDhkVXEyd0NFZEJITVN1YzUzNE1tNkFVUjhSMjV5bXNZUDl0MElValBJLVgxdE01d1JGcTJJSGNHM1N0SlB3VWZFSjVEZUlMYm9xbWh2elZOR0NxR2IxbVVDckN4dzZya1N5TkxPTmx5d2JMTUlHNlJzMXFLR1R5U2ZaMm1ISldwU1FycUVaU3JVY0l6c3RiUE10cE5nOF84UHRLWEhUc2k4VGdQTGdJNWg0eTF6dW91VnNzcGdQY2g5clJsM24wZlgtcGhPSnVuQzZwUlNja0Z3U25MY002LVJuSzV3aVNHM21J?oc=5","date":"2025-09-18","type":"deal","source":"msn.com","summary":"RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - msn.com","headline":"RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQM05vZXRORmtLbzlOdC1HNDI4b0dVUU5NMlVVeGlsd2sxNkFsb3ZRVVE2Rk1zS3Z6X2VOOXZ3NUZnLU4yZ2RpVTA0cThhakpNaUxiSTZDa1g4azB5VHozaW9kUXhZcXFZVjhONGVQZEg3NE9ZUVNpbVU3cEo3eWJ6YmVRbVFtUQ?oc=5","date":"2025-07-30","type":"pipeline","source":"Pharmaceutical Technology","summary":"ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture - Pharmaceutical Technology","headline":"ViroCell and AvenCell to advance allogeneic CAR-T therapy manufacture","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPaHZWNlpNa1RaankyZTJuWmdnSjl0WXQ2SjlHVXJZU3hEN0otTjBZZmU3bGdfM0xGbGxHa1RBZVJaTXdkSHBDTGI1azZKaC1fQVdTaHFQQ0M5ekp5UWZQWGVxYWwyVVlOTWVkOW50UG5qakktUzVzSmE1Z2FJeG1zMVE3LVdxak5ZS1lvUExqT2FxbmY5OVBTYXhpTjFxTXhLeXNOeEdMNlVfN0tTMWtSVy1EYnFlenVKUkdqSjZDbkQ4UGd0bmpwc2ZDSjAzWXk5SHhfMUhWdW9mbVVWcHcwRTlkTzBOZw?oc=5","date":"2025-07-29","type":"pipeline","source":"Contract Pharma","summary":"ViroCell Biologics Delivers Novel Retroviral Vector to AvenCell Therapeutics for Allogeneic CAR-T Therapy - Contract Pharma","headline":"ViroCell Biologics Delivers Novel Retroviral Vector to AvenCell Therapeutics for Allogeneic CAR-T Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAJBVV95cUxNTnFncTZHc3ZKQnhOVnFVbnUzNkdLOXlDSTRYS2J4dzZSMy1LV215OV9lWWZXcFB2MmVsV0Z0WFFJVGZtMzJTZ29EV1V4MS1zU0hkMUxFWUUzeHBnTWp0RzhXX1hqYUpfdWV2RlBLTUQtZUtGeElJejVBbXQ2SHhnQlJsQk1pX0dadFc2aUh3N016UFdudS0xVlo5TzdnZ04tU1p6eWNtOHFNWW1aZmJ3eUM4M3JUTUdHWFNuRUlQeUxGaVVxU2VWM2xkS0hxZUl4NDJHSHBYUXlOU1VIQXdtc085RnZNLU5GM1E3M1dDcVgxLTVWM3J4dEg2cGl0bWdwMnZtQkJIWTZ4anBlZ1U2cFRHOEQxRERtMjlGb0RlY0RhRXowdFpxMVFEblp6bldyaXNWUnIzLU8xUS1YTnVnbg?oc=5","date":"2025-07-29","type":"deal","source":"BioSpace","summary":"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers - BioSpace","headline":"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Develo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNRTVBaU5adXAzY0s1OS1GNFE3N1NNa0ZtWWFicEpweVYzV1BwMWU2SXlBd1AyeVlEWTh1a0JiejQ0cW5PZE1JWTVaRVhmZ2ZyVDBBYnViWFA1QnZmOVZ6enpvaGNxWjNpVGhyQ2wxY05kTlZRa015V0FhaHJRZkpUQXhJVUZFa1ZRQTFLaDFaeFV1TEQzQm1VdjhJTDA4M1ZicWlucHlyUU5vT3NqaXJHUmI3amVEaXFIU0k1cGwzTzZ4Nnk2clcyRjlncHZvc0tRRnc?oc=5","date":"2025-06-30","type":"pipeline","source":"PR Newswire","summary":"AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program - PR Newswire","headline":"AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOdE11cjhVYUNIVnJzRF9jVzZJVkdQNVFRbi1HWlVVcTJXai1BUkhKek4xZnpZZ2k4T1FHYTFpZHRELWVaYmdLVnV6eDR5LXEtQk1jS3VidTVTSko5VzJwWk5WLWpCc2RvMlJzUmRQNEstM1R0SWlTRW9TZjNCVWt2NVhVeWVPM2ZYSDVmVXNBVXJnYkxIczZnYWxzeFFvQWdiUFZUZDVMektmMXF2aVB2ME1DSzBYUWw2XzJYV3VpRVU5QQ?oc=5","date":"2024-10-22","type":"pipeline","source":"PR Newswire","summary":"AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings - PR Newswire","headline":"AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdings","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}